XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
"Cell bank characterization data are incomplete — testing for adventitious viruses per the ICH Q5A(R2) panel has not been conducted at the MCB level." This deficiency, issued by FDA for a commercial BLA application,
View details →
Stability data is the most data-rich component of any CMC submission — and the PQ-CMC structured format for stability data is designed to make that data machine-readable, cross-referenceable, and comparable across submissions in ways
View details → An upstream bioreactor process description for a monoclonal antibody that specifies inoculation density, bioreactor volume, pH range, dissolved oxygen setpoint, and temperature — but does not address the metabolic trajectory of the culture, the
View details → Every EU marketing authorisation holder that has not registered its active substances in EMA's Substance Management Service is already experiencing submission delays and data reconciliation problems — and most of them don't yet know
View details → "Viral clearance data from scaled-down studies have not been provided for two of the chromatography steps — please provide the validation data or a scientific justification for omission." This deficiency, common in BLA CMC
View details → "When FDA convenes an advisory committee to examine how it evaluates CMC packages, it is signaling the direction of reviewer expectations before those expectations appear in final guidance — and the companies that read
View details →
Cleaning validation is one of the most frequently cited deficiency areas in FDA pre-approval inspections — not because companies have not validated their cleaning processes, but because the cleaning validation strategy does not withstand
View details → Every analytical challenge in LNP characterization flows from a single structural reality: you are measuring a four-component nanoparticle system whose identity, purity, and activity emerge from the precise spatial arrangement of those components in
View details →
FDA's 2022 Computer Software Assurance guidance is not a minor update to the IQ/OQ/PQ validation framework — it is a conceptual redesign of how pharmaceutical companies should approach GMP software compliance, and organizations that
View details → ICH Q2(R2) reached ICH Step 4 in 2023 and was issued as final FDA guidance in March 2024 and introduced changes to analytical method validation that go beyond terminology updates — the revised guideline
View details → "The regulatory framework for lipid nanoparticle drug products is still being built in real time. Understanding which regulatory framework applies to your LNP program — and how to navigate the jurisdiction question within FDA
View details → The most common reason FDA issues a Complete Response Letter for CMC deficiencies related to specifications is not that the acceptance criteria are wrong — it is that the submission does not contain the
View details → PEG-lipid is a structural component of every approved LNP drug product. Without it, the LNP as a systemic delivery vehicle does not function. And yet PEG-lipid brings with it a pharmacological liability that has
View details → A post-approval manufacturing change that required a Prior Approval Supplement but was submitted as a Changes Being Effected in 30 Days notification is not a submission strategy — it is a regulatory violation that
View details → Patisiran (Onpattro) was approved by FDA on August 10, 2018 — the first RNA interference drug product to receive regulatory approval anywhere in the world, delivered in an LNP formulation using DLin-MC3-DMA as the
View details → The Annual Product Review — or Product Quality Review as EU GMP calls it — is one of the most universally produced and most universally underutilized documents in pharmaceutical manufacturing, and the companies that
View details →
The COVID-19 mRNA vaccine programs created a widespread assumption that the CMC framework developed for mRNA vaccines applies directly to mRNA therapeutics. It does not — not entirely — and understanding the differences is
View details → When FDA issues a 483 observation for inadequate control of materials, the citation almost always traces back to a supplier qualification program that checked a box rather than built a quality system — a
View details →